Recent Changes in Durable Left Ventricular Assist Device Bridging to Heart Transplantation.
Journal
ASAIO journal (American Society for Artificial Internal Organs : 1992)
ISSN: 1538-943X
Titre abrégé: ASAIO J
Pays: United States
ID NLM: 9204109
Informations de publication
Date de publication:
01 02 2022
01 02 2022
Historique:
pubmed:
1
4
2021
medline:
2
2
2022
entrez:
31
3
2021
Statut:
ppublish
Résumé
This study evaluates the impact of the recent United Network for Organ Sharing (UNOS) allocation policy change on outcomes of patients bridged with durable left ventricular assist devices (LVADs) to orthotopic heart transplantation (OHT). Adults bridged to OHT with durable LVADs between 2010 and 2019 were included. Patients were stratified based on the temporal relationship of their OHT to the UNOS policy change on October 18, 2018. The primary outcome was early post-OHT survival. In total, 9,628 OHTs were bridged with durable LVADs, including 701 (7.3%) under the new policy. Of all OHTs performed during the study period, the proportion occurring following durable LVAD bridging decreased from 45% to 34% (p < 0.001). The more recent cohort was higher risk, including more extracorporeal membrane oxygenation bridging (2.6% vs. 0.3%, p < 0.001), more mechanical right ventricular support (9.7% vs. 1.4%, p < 0.001), greater pretransplant ICU admission (22.8% vs. 8.7%, p < 0.001) more need for total functional assistance (62.8% vs. 53.0%, p < 0.001), older donor age (33.3 vs. 31.7 years, p < 0.001), and longer ischemic times (3.38 vs. 3.13 hours, p < 0.001). Despite this, early post-OHT survival was comparable at 30 days (96.1% vs. 96.0%, p = 0.89), 90 days (93.7% vs. 94.0%, p = 0.76), and 6 months (91.0% vs. 93.0%, p = 0.96), findings that persisted after risk-adjustment. In this early analysis, OHT following bridging with durable LVADs is performed less frequently and in higher risk recipients under the new allocation policy. Despite this, short-term posttransplant outcomes appear to be unaffected in this patient cohort in the current era.
Identifiants
pubmed: 33788800
doi: 10.1097/MAT.0000000000001436
pii: 00002480-202202000-00010
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
197-204Informations de copyright
Copyright © ASAIO 2021.
Références
Mehra MR, Uriel N, Naka Y, et al.; MOMENTUM 3 Investigators: A fully magnetically levitated left ventricular assist device—final report. N Engl J Med 2019.380: 1618–1627
Truby LK, Garan AR, Givens RC, et al.: Ventricular assist device utilization in heart transplant candidates: nationwide variability and impact on waitlist outcomes. Circ Heart Fail 2018.11: e004586
Thoracic Organ Transplantation Committee U: OPTN/UNOS Policy Notice Proposal to Modify the Adult Heart Allocation SystemA (RRB and Committee Review of Exceptions), 6.3.B (Exceptions to Allocation for Sensitized Candidates Problem Statement. Available at: https://optn.transplant.hrsa.gov/media/2028/thoracic_policynotice_201612.pdf . Accessed January 10, 2020.
Yin MY, Wever-Pinzon O, Mehra MR, et al.: Post-transplant outcome in patients bridged to transplant with temporary mechanical circulatory support devices. J Heart Lung Transplant 2019.38: 858–869
Ouyang D, Gulati G, Ha R, Banerjee D: Incidence of temporary mechanical circulatory support before heart transplantation and impact on post-transplant outcomes. J Heart Lung Transplant 2018.37: 1060–1066
Fukuhara S, Takeda K, Polanco AR, Takayama H, Naka Y: Prolonged continuous-flow left ventricular assist device support and posttransplantation outcomes: A new challenge. J Thorac Cardiovasc Surg 2016.151: 872–880.e5
Grosman-Rimon L, Ajrawat P, Lioe J, et al.: Increases in serum autoantibodies after left ventricular assist device implantation. J Card Fail 2019.25: 301–306
Kransdorf EP, Kittleson MM, Patel JK, Pando MJ, Steidley DE, Kobashigawa JA: Calculated panel-reactive antibody predicts outcomes on the heart transplant waiting list. J Heart Lung Transplant 2017.36: 787–796
Ko BS, Drakos S, Kfoury AG, et al.; Utah Transplant Affiliated Hospitals (U.T.A.H.) Cardiac Transplant Program: Immunologic effects of continuous-flow left ventricular assist devices before and after heart transplant. J Heart Lung Transplant 2016.35: 1024–1030
John MM, Shih W, Estevez D, et al.: Interaction between ischemic time and donor age on adult heart transplant outcomes in the modern era. Ann Thorac Surg 2019.108: 744–748
Gaffey AC, Chen CW, Chung JJ, et al.: Extended distance cardiac allograft can successfully be utilized without impacting long-term survival. J Heart Lung Transplant 2017.36: 968–972
Crawford TC, Magruder JT, Grimm JC, et al.: The paradoxical relationship between donor distance and survival after heart transplantation. Ann Thorac Surg 2017.103: 1384–1391
Kilic A, Hickey G, Mathier M, et al.: Outcomes of adult heart transplantation using hepatitis C–positive donors. J Am Heart Assoc 2020.9: e014495
Cogswell R, John R, Estep JD, et al.: An early investigation of outcomes with the new 2018 donor heart allocation system in the United States. J Heart Lung Transplant 202039: 1–4
Nativi JN, Kfoury AG, Myrick C, et al.: Effects of the 2006 U.S. thoracic organ allocation change: Analysis of local impact on organ procurement and heart transplantation. J Heart Lung Transplant 201029: 235–239
Singh TP, Almond CS, Taylor DO, Graham DA: Decline in heart transplant wait list mortality in the United States following broader regional sharing of donor hearts. Circ Heart Fail 2012.5: 249–258
Wever-Pinzon O, Drakos SG, Kfoury AG, et al.: Morbidity and mortality in heart transplant candidates supported with mechanical circulatory support: Is reappraisal of the current United network for organ sharing thoracic organ allocation policy justified? Circulation 2013.127: 452–462
Schulze PC, Kitada S, Clerkin K, Jin Z, Mancini DM: Regional differences in recipient waitlist timeand pre- and post-transplant mortality after the 2006 united network for organ sharing policy changes in the donor heart allocation algorithm. JACC: Heart Failure 2014.2: 166–177